Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors.
Photodynamic therapy (PDT) ablates malignancies by applying focused near-infrared (nIR) light onto a lesion of interest after systemic administration of a photosensitizer (PS); however, the accumulation of existing PS is not tumor-exclusive. We developed a tumor-localizing strategy for PDT, exploiting the high expression of heat shock protein 90 (Hsp90) in cancer cells to retain high concentrations of PS by tethering a small molecule Hsp90 inhibitor to a PS (verteporfin, VP) to create an Hsp90-targeted PS (HS201). HS201 accumulates to a greater extent than VP in breast cancer cells both in vitro and in vivo, resulting in increased treatment efficacy of HS201-PDT in various human breast cancer xenografts regardless of molecular and clinical subtypes. The therapeutic index achieved with Hsp90-targeted PDT would permit treatment not only of localized tumors, but also more diffusely infiltrating processes such as inflammatory breast cancer.
Duke Scholars
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Verteporfin
- Photosensitizing Agents
- Photochemotherapy
- MCF-7 Cells
- Humans
- HSP90 Heat-Shock Proteins
- Cell Line, Tumor
- Antineoplastic Agents
- 32 Biomedical and clinical sciences
- 31 Biological sciences
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Verteporfin
- Photosensitizing Agents
- Photochemotherapy
- MCF-7 Cells
- Humans
- HSP90 Heat-Shock Proteins
- Cell Line, Tumor
- Antineoplastic Agents
- 32 Biomedical and clinical sciences
- 31 Biological sciences